Skip to main content

Table 2 Mean urinary (±SD) concentrations of ten biomarkers assessed by ELISA in cohort of 288 subjects

From: A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort

Biomarker Total bladder cancer Low-grade bladder cancer High-grade bladder cancer NMIBC MIBC Controls
(75.9 %) (41.2 %) (58.8 %) (80.6 %) (19.4 %) (24.1 %)
n = 211 n = 87 n = 124 n = 170 n = 41 n = 67
IL8 (pg/mL)abc 1.224 ± 1.387 0.763 ± 0.824 1.547 ± 1.598 1.020 ± 1.177 2.070 ± 1.826 0.566 ± 0.464
MMP9 (ng/mL)abc 0.485 ± 0.536 0.311 ± 0.261 0.607 ± 0.638 0.411 ± 0.434 0.792 ± 0.770 0.319 ± 0.366
SERPINA1 (ng/mL)abc 2.648 ± 2.538 1.891 ± 1.594 3.180 ± 2.920 2.312 ± 2.147 4.041 ± 3.444 1.061 ± 0.711
ANG (pg/mL)abc 2.133 ± 1.181 1.812 ± 0.928 2.358 ± 1.286 1.979 ± 1.037 2.770 ± 1.504 1.190 ± 0.543
VEGF (pg/mL)abc 1.852 ± 1.021 1.570 ± 0.610 2.050 ± 1.193 1.731 ± 0.897 2.352 ± 1.322 1.386 ± 0.395
CA9 (pg/mL)abc 0.770 ± 0.971 0.577 ± 0.480 0.905 ± 1.185 0.668 ± 0.805 1.190 ± 1.411 0.357 ± 0.242
MMP10 (pg/mL)abc 0.989 ± 1.625 0.626 ± 0.422 1.243 ± 2.055 0.814 ± 1.346 1.713 ± 2.353 0.517 ± 0.492
APOE (pg/mL)abc 0.639 ± 0.427 0.491 ± 0.307 0.744 ± 0.468 0.571 ± 0.373 0.923 ± 0.518 0.420 ± 0.177
SERPINE1 (ng/mL)abc 0.156 ± 0.181 0.096 ± 0.080 0.198 ± 0.217 0.125 ± 0.134 0.284 ± 0.273 0.056 ± 0.030
SDC1 (pg/mL)a 0.489 ± 0.140 0.468 ± 0.127 0.504 ± 0.147 0.478 ± 0.129 0.534 ± 0.172 0.331 ± 0.121
  1. NMIBC non-muscle invasive bladder cancer, MIBC muscle invasive bladder cancer
  2. a P < 0.05 comparing total bladder cancer to total controls
  3. b P < 0.05 comparing low-grade bladder cancer to high-grade bladder cancer
  4. c P < 0.05 comparing NMIBC to MIBC